OncoMatch/Clinical Trials/NCT07663357
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
Is NCT07663357 recruiting? Yes, currently enrolling (Jul 2026).
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Lab requirements
Kidney function
chronic kidney disease and a glomerular filtration rate (GFR) < 30 mL/min/1.73 m² [excluded]
Cardiac function
left ventricular ejection fraction (LVEF) < 50% [excluded]; uncontrolled hypertension [excluded]; complex congenital heart disease [excluded]
Patients with a left ventricular ejection fraction (LVEF) < 50%; Patients with chronic kidney disease and a glomerular filtration rate (GFR) < 30 mL/min/1.73 m²; Patients with uncontrolled hypertension; Patients with complex congenital heart disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07663357 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages